Current Science

Open Access Open Access  Restricted Access Subscription Access

Intellectual Property Evolution and Innovation Ecosystem as Effective Tools in Strengthening Indian Healthcare Sector


Affiliations
1 Indian Council of Medical Research, New Delhi 110 029, India
2 Amity Directorate of Science and Innovation, Amity University, Noida 201 313, India
 

Despite India’s enormous technological potential, indigenous medicinal knowledge and various initiatives by the government and industry at translational cycle, the country carries a global disease burden of 21%, majorly contributed by dual disease burden. Public health faces the major anomalies of 3A (accessibility, affordability, availability) of the healthcare sector, possibly due to restrictive coordination among stakeholders, transiting disease profile, undeveloped delivery system and regulatory mechanisms. This article emphasizes the significance of integrative approach of using our research and development strength and establishing a strong intellectual property system for conducive healthcare environment, accentuating the significance of 3P (public–private partnership) in addressing the major anomalies of 3A.

Keywords

Healthcare, Innovation Ecosystem, Intellectual Property, Public–Private Partnership.
User
Notifications
Font Size

  • MoHFW, Draft National Health Policy 2015, Ministry of Health & Family Welfare, Government of India (GoI), 2014; http://www.mohfw.nic.in/showfile.php?lid=3014

  • MoHFW, Situational analyses: Backdrop to the national Health policy 2017, Ministry of Health and Family Welfare, GoI.

  • Non-communicable diseases (NCD) Country Profiles, World Health Organization (WHO), Geneva, 2014, p. 91.

  • Kathleen, F. B. et al., Impacts of climate change on public health in India: future research directions. Environ. Health Perspect., 2011, 119, 765–770.

  • The Burden of Disease among India’s Urban Poor – A Study at Three Sites, The Micro Insurance Academy, New Delhi, 2012.

  • WHO, Global status report on noncommunicable diseases 2014, noncommunicable diseases and mental health – World Health Organization, 2014.

  • Ghosh, S. and Arokiasamy, P., Morbidity in India. J. Health Stud., 2009, 2, 136–148.

  • WHO, Countries-India, World Health Organization, 2016; http://www.who.int/countries/ind/en/.

  • Dye, C., After 2015: infectious diseases in a new era of health and development. Philosophical Trans. R Soc. London Ser. B, 2014, 369, 1645.

  • Planning Commission, 9th Five-Year Plan, GoI, 1997, vol. 11; http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4024220/

  • WHO, Country Cooperation Strategy. World Health Organization, Geneva, 2015; http://apps.who.int/iris/bitstream/10665/136895/1/ccsbrief_ind_en.pdf.

  • National Commission on Macroeconomics and Health, NCMH background papers – Burden of disease in India. GoI, Shree Om Enterprises Pvt Ltd, 2005; http://www.who.int/macrohealth/action/NCMH_Burden%20of%20disease_(29%20Sep%202005).pdf

  • Desai, N., Investment in Healthcare Sector in India, Nishith Desai Associates, Report, Mumbai, 2016.

  • National Sample Survey Office, Ministry of Statistics and Programme Implementation, Government of India, Key Indicators of Social Consumption in India Health, NSS 71st round (January–June 2014).

  • Gaidhane, A. and Quazi, S. Z., Injection practices in India – IPEN Study Group. WHO South-East Asia J. Publ. Health, 2012, 1(2), 189–200.

  • Healthcare sector to touch $280 bn by 2020: FICCI, Business Standard; http://www.business-standard.com/article/economy-policy/healthcare-sector-to-touch-280-bn-by-2020-ficci-1100906-00170_1.html (accessed on 20 October 2016).

  • Berman, P. et al., The impoverishing effect of health care payments in India. Econ. Polit. Wkly, 2010, 16, 65.

  • Jaiswal, R. K., Sinha, A., Munjal, P., Sharma, S., Sangita, S. and Paul, S., Healthcare in India: challenges and possibilities. Macro Track January 2014, National Council of Applied Economic Research, 2014.

  • Government sponsored health insurance in India: are you covered? The World Bank, 2012; http://www.worldbank.org/en/news/feature/2012/10/11/government-sponsored-health-insurance-in-india-are-you-covered

  • Mehra, P., Only 17% have health insurance cover. The Hindu, 2016.

  • Medical devices: making in India – a leap for Indian healthcare. Deloitte and Nat Health, New Delhi, 2016; https://www2.deloitte.com/in/en/pages/life-sciences-andhealthcare/articles/medical-devices-making-in-india.html

  • Buy Indian medical devices, states told. Deccan Herald, 9 August 2016.

  • Kaul, R., Govt notifies medical devices rules 2017. Hindustan Times, 2017.

  • Coronary stents set to get cheaper. The Times of India, 2016.

  • The Grant Thronton, Progressive change – impetus to medical technology through innovation, incentivisation and regulation (eds Mathur, V. and Shankar, S.), In 6th Medical Technology Conference – Medical Technology and its Vital Place in Healthcare in India, New Delhi, 2013; http://www.grantthornton.in/en/insights/articles/progressive-change-impetus-to-medical-technology-through-innovation-incentivisation-and-regulation/

  • Arrowsmith, J., Trial watch: phase II failures: 2008–2010. Nature Rev. Drug Discov., 2011, 10, 328–329.

  • India Brand Equity Foundation, Indian healthcare industry analysis, 2016; http://www.ibef.org/ (accessed on 26 October 2016).

  • Raghvan, P., Budget 2016: Medical device industry hopes for ‘Make in India’ sops. The Economic Times, 2016; http://economictimes.indiatimes.com/industry/healthcare/biotech/health-care/budget-2016-medical-device-industry-hopes-for-make-in-india-sops/articleshow/51177970.cms

  • Kumar, V., Future growth of medical device market in India as compared to the global market. The Economic Times, 2015; http://health.economictimes.indiatimes.com/health-files/future-growth-of-medical-device-market-in-india-as-compared-to-the-global-market/628

  • Govt plans a slew of policy measures to give critical push to medical technology sector: DoP secretary. Pharmabiz, 2015.

  • Chakravarthi, I., Medical equipment industry in India: production, procurement and utilization. Indian J. Public Health, 2013, 57, 203–207.

  • Paul, S., Mytelka, D., Dunwiddie, C., Persinger, C., Munos, B., Linborg, S. and Schacht, A., How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat. Rev. Drug Discov., 2017, 9, 203–214.

  • Sakthivel Selvaraj, S. and Karan, A. K., Deepening health insecurity in India: evidence from National sample surveys since 1980s. Econ. Polit. Wkly, 2009, 44, 40; http://re.indiaenvironmentportal.org.in/files/Deepening%20Health%20Insecurity%20in%20India.pdf

  • Van, D., Donnell, O., Eliya, R. P., Somamathan, A., Adhikari, S. R. and Garg, C. C., Effects of payments or health care on poverty estimates in 11 countries in Asia: an analysis of household survey data. Lancet, 2006, 368, 1357–1364.

  • DST, Science, Technology and Innovation Policy 2013. Department of Science & Technology, GoI, 2013; http://dst.gov.in/st-system-india/science-and-technology-policy-2013

  • Adroley, N. and Palnitkar, U., Union Budget 2016 – Pharmaceuticals, KPMG, 2016; http://www.kpmg.com/IN/budget2016

  • National Science and Technology Management Information System, Directory of Research and Development Institutions 2015, DST, 2015.

  • National Science and Technology Management Information Systems, Final Research and Development Statistics at a Glance 2011–12, DST, 2013.

  • National Science and Technology Management Information Systems, International Comparative Performance of India’s Research Base (2009–14), DST, 2015.

  • National Science and Technology Management Information Systems, India’s Research Output and Collaboration (2005–14): A Bibliometric Study Phase-II, DST, 2015.

  • Sharma, S., Just 4 institutes account for a third of India’s research output, Hindustan Times, New Delhi, 2016.

  • Shiva, V., The turmeric patent is just the first step in stopping biopiracy. Third World Network, 1997, p. 86; http://www.twn.my/title/tur-cn.htm

  • The Office of the Controller General of Patents, Designs, Trademarks and Geographical Indications, Annual Report 2014–15, Department of Industrial Policy and Promotion, 2016.

  • Hoen, E., Private patents and public health: changing intellectual property rules for access to medicines, Health Action International, Amsterdam, The Netherlands, 2016.

  • India’s Patents (Amendment) Act, 2005 (Act No. 15 of 2005), WIPO Lex, 2005; http://www.wipo.int/wipolex/en/details.jsp?id=2407.

  • India blocks colgate patents for spices, Deccan Herald, New Delhi, 2015.

  • Kulkarni, K. and Mohanty, S., Novartis loses landmark India patent case on Glivec. Reuters, Mumbai, 2013.

  • Sivaraman, R., Natco Pharma wins cancer drug case. The Hindu, Chennai, 2013.

  • MoHFW, National Health Policy 2017, Ministry of Health and Family Welfare, GoI, 2017; http://www.mohfw.nic.in/index1.php?lang=1&level=1&sublinkid=6471&lid=4270

  • 1.3% of GDP spent on healthcare in 2015–16 by Centre and States. The Economic Times, 2016.

  • Indian Medical Electronics Industry Outlook, 2020, Deloitte, 2011; https://www2.deloitte.com/kr/ko/pages/life-sciences-and-healthcare/articles/indian-medical-electronics-industry-outlook-2020-20120109.html

  • Rajagopal, D., Patented drug launches help MNCs score over Indian peers. The Economic Times, Mumbai, 2017.

  • Healthcare Industry Analysis, India Brand Equity Foundation, Indian, 2016; http://www.ibef.org/ (accessed on 26 October 2016).

  • Sanghi, S. and Sirija, A., Make in India and the potential for job creation. Confederation of Indian Industry – Focus in Sector, New Delhi, 2015.

  • Dinesh, P., Indian medical device industry – current state and opportunities for growth, Infosys, 2015.

  • Dey, S., Prices of key drugs down 35 per cent. The Times of India, 2016.

  • Dhananjay, M., Centre can fix drug prices to check profiteering: SC, The Times of India, New Delhi, 2016.

  • Coronary stents set to get cheaper. The Times of India, 2016.

  • Francis, P. A., Relaxing clinical trial rules. Pharmabiz, 2016.

  • MoHFW, National Rural Health Mission, 2005; http://nrhm.gov.in/nhm/nrhm.html

  • MoHFW, National Urban Health Mission, 2013; http://nrhm.gov.in/nhm/nuhm.html

  • National Intellectual Property Rights Policy 2016, Department of Industrial Policy and Promotion, Ministry of Commerce and Industry, Government of India, 2016.

  • Prime Minister’s Fellowship Scheme for Doctoral Research, Science & Engineering Research Board (SERB) and Confederation of Indian Industry (CII), 2014; http://www.primeministerfellowshipscheme.in

  • Twelfth Five-Year Plan (2012–2017), Planning Commission, GoI, 2012, vol. 1; http://planningcommission.gov.in/plans/planrel/12thplan/welcome.html

  • Start-up India, Department of Ministry of Commerce and Industry, GoI, 2015; http://www.startupindia.gov.in/index.php


Abstract Views: 276

PDF Views: 93




  • Intellectual Property Evolution and Innovation Ecosystem as Effective Tools in Strengthening Indian Healthcare Sector

Abstract Views: 276  |  PDF Views: 93

Authors

Tripta Dixit
Indian Council of Medical Research, New Delhi 110 029, India
Sadhana Srivastava
Indian Council of Medical Research, New Delhi 110 029, India
Smita Sahu
Amity Directorate of Science and Innovation, Amity University, Noida 201 313, India
W. Selvamurthy
Amity Directorate of Science and Innovation, Amity University, Noida 201 313, India

Abstract


Despite India’s enormous technological potential, indigenous medicinal knowledge and various initiatives by the government and industry at translational cycle, the country carries a global disease burden of 21%, majorly contributed by dual disease burden. Public health faces the major anomalies of 3A (accessibility, affordability, availability) of the healthcare sector, possibly due to restrictive coordination among stakeholders, transiting disease profile, undeveloped delivery system and regulatory mechanisms. This article emphasizes the significance of integrative approach of using our research and development strength and establishing a strong intellectual property system for conducive healthcare environment, accentuating the significance of 3P (public–private partnership) in addressing the major anomalies of 3A.

Keywords


Healthcare, Innovation Ecosystem, Intellectual Property, Public–Private Partnership.

References





DOI: https://doi.org/10.18520/cs%2Fv114%2Fi08%2F1639-1649